China’s BeiGene raises $175m from follow-on

Jonathan Breen

August 11, 2017 10:30 AM

Capsules_230px

Nasdaq-listed Chinese biopharmaceutical firm BeiGene has bagged $175m from a follow-on public offering of American Depositary Shares (ADSs).

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity China Americas Asia Follow-ons and Rights Issues Asia Greater China Morgan Stanley Northeast Asia Asia Pacific United States Follow-ons and Rights issues Emerging Markets North America Goldman Sachs

JB

Jonathan Breen

Equities editor GlobalCapital Asia